Literature DB >> 1349621

In vivo protection by the aminothiol WR-2721 against neutron-induced carcinogenesis.

B A Carnes1, D J Grdina.   

Abstract

The ability of the compound S-2-(aminopropylamino)ethylphosphorothioic acid, designated WR-2721, to protect against neutron-induced carcinogenesis was investigated. Both sexes of the B6CF1 mouse were injected i.p. with 400 mg/kg of WR-2721 30 min prior to being irradiated by 10 cGy of neutrons. Neoplastic mortality in the groups receiving thiol was either reduced or delayed relative to irradiated mice not given protector. However, the time at which the protective effect of WR-2721 was expressed depended on the sex of the animal. Thiol-related shifts in the time of neoplastic death in females occurred only in the first half of the lifespan. Once a female survived to the mean age at death, no difference in the pattern of mortality could be detected between control and WR-2721-treated mice exposed to neutrons. Irrespective of thiol treatment, the timing of tumour-related death was nearly identical during the first half of life for males exposed to neutrons. In the last half of the lifespan, survival of thiol-protected males was enhanced relative to saline-injected males and even exceeded that observed in the control population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349621     DOI: 10.1080/09553009214551381

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  11 in total

1.  Alteration of radiation-sensitive processes associated with cancer and longevity by dietary 2-mercaptoethanol.

Authors:  Robert E Click
Journal:  J Cancer Res Ther       Date:  2014 Jan-Mar       Impact factor: 1.805

2.  Biological Effects of Space Radiation and Development of Effective Countermeasures.

Authors:  Ann R Kennedy
Journal:  Life Sci Space Res (Amst)       Date:  2014-04-01

3.  Antioxidant dietary supplementation in mice exposed to proton radiation attenuates expression of programmed cell death-associated genes.

Authors:  J K Sanzari; C Wambi; J S Lewis-Wambi; A R Kennedy
Journal:  Radiat Res       Date:  2011-03-28       Impact factor: 2.841

Review 4.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Tissue and data archives from irradiation experiments conducted at Argonne National Laboratory over a period of four decades.

Authors:  Qiong Wang; Tatjana Paunesku; Gayle Woloschak
Journal:  Radiat Environ Biophys       Date:  2010-03-23       Impact factor: 1.925

6.  WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability.

Authors:  Jaroslaw Dziegielewski; Janet E Baulch; Wilfried Goetz; Mitchell C Coleman; Douglas R Spitz; Jeffrey S Murley; David J Grdina; William F Morgan
Journal:  Free Radic Biol Med       Date:  2008-09-18       Impact factor: 7.376

7.  Effects of thiols on topoisomerase-II alpha activity and cell cycle progression.

Authors:  D J Grdina; J S Murley; J C Roberts
Journal:  Cell Prolif       Date:  1998 Oct-Dec       Impact factor: 6.831

8.  Modulation of radiation-induced life shortening by systemic intravenous MnSOD-plasmid liposome gene therapy.

Authors:  Michael W Epperly; Tracy Dixon; Hong Wang; James Schlesselman; Darcy Franicola; Joel S Greenberger
Journal:  Radiat Res       Date:  2008-10       Impact factor: 2.841

Review 9.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

Review 10.  Heavy ions, radioprotectors and genomic instability: implications for human space exploration.

Authors:  Jaroslaw Dziegielewski; Wilfried Goetz; Janet E Baulch
Journal:  Radiat Environ Biophys       Date:  2009-12-25       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.